TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04412330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICU Recovery + Physical Therapy
Description: Physical therapy interventions will be supervised by a physical therapist (\>20 years of experience in ICU and pulmonary rehabilitation). Potential interventions include endurance/aerobic training (treadmill training, upper and lower extremity ergometer, and recumbent step machine), upper and lower extremity resistance strength training, balance training, functional movement training, and education. If the interventions are providing in the home environment the exercises will be completed through Zoom, video communications app. Home-based interventions will include seated and standing exercise including resistance exercises (such as lifting small weights) and endurance (e.g. marching or stepping in place, repetitive sit-to-stand training). Physical therapist will provide verbal instructions for motivation and adherence to exercise interventions.
Study: NCT03769272

Intervention type: PROCEDURE
Intervention: Measurement of electrical delay during LV lead placement
Description: Measurement of electrical signal in the heart during implantation of CRT, by positioning the lead in different places in the heart.
Study: NCT03818516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Participants will undergo a fasting blood draw for inflammatory and metabolic markers before a 75gm oral glucose tolerance test (OGTT) and at 1, 2 and 3 hours post-OGTT. Behavioral assessments will also be administered pre- and post-OGTT administration.
Study: NCT04037553

Intervention type: OTHER
Intervention: Intracuff pressure measurement
Description: Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.

Intervention type: OTHER
Intervention: Intracuff pressure measurement
Description: Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.

Intervention type: OTHER
Intervention: Intracuff pressure measurement
Description: Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
Study: NCT01487889

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatty acid composition of complementary food
Description: Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatty acid composition of complementary food
Description: Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatty acid composition of complementary food
Description: Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
Study: NCT05929625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-585-2 RF+US
Description: The subjects of RF+US group will receive four simultaneous RF+US treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-585-2 RF
Description: The subjects of RF only study group will receive four RF treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
Study: NCT01202630

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus CL1285® and Lactobacillus casei
Description: 2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules of placebo (no live cells), consumed once daily for 60 days
Study: NCT00120965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoPulse
Description: Standard device settings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual CPR
Description: Manual CPR
Study: NCT02799498

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto-injector device
Description: Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)

Intervention type: OTHER
Group type: OTHER
Intervention: Etanercept (ENBREL®) via Manual injection
Description: Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept (ENBREL®)
Description: Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
Study: NCT02231684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
Study: NCT03240770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VPro5 device
Description: Use of the VPro5 device for 5 minutes a day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VPro5 device
Description: Use of the VPro5 device for 5 minutes a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deviation from Standard Tray Wear Time (14 Days)
Description: Patients reduced Tray Wear Time Interval (14 Days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deviation from Standard Tray Wear Time (14 Days)
Description: Patients reduced Tray Wear Time Interval (14 Days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deviation from Standard Tray Wear Time (14 Days)
Description: Patients reduced Tray Wear Time Interval (14 Days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deviation from Standard Tray Wear Time (14 Days)
Description: Patients reduced Tray Wear Time Interval (14 Days)
Study: NCT02762214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clermont-Ferrand Uterine Manipulator
Description: Pelvic cytology is obtained before starting surgical procedures (washing number 1).~After tubal coagulation, Clermont-Ferrand Uterine Manipulator is installed inside the uterus. At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No uterine Manipulator
Description: Pelvic cytology is obtained before starting surgical procedures (washing number 1). None uterine manipulator is used and the cervix is closed with a cross stitch.~Tubal coagulation, At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)
Study: NCT00308971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha, gamma, beta, and delta (mixed) tocopherols
Description: approximately 666 IU daily (1 pill) for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha lipoic acid
Description: 600 mg daily (2 pills 300 mg each) for 4 months
Study: NCT02452151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab-Biosimilar

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab-Innovator
Study: NCT05037838

Intervention type: PROCEDURE
Intervention: Longitudinal strain obtained thanks to transesophageal ultrasound data recorded during liver transplantation
Description: Longitudinal strain of Left Ventricule and longitudinal strain of Right Ventricule free wall obtained thanks to TransEosophagal Ultrasound performed during the Liver Transplant
Study: NCT03305510

Intervention type: DIAGNOSTIC_TEST
Intervention: vitamin D is below 20ng/ml
Study: NCT02703636

Intervention type: DRUG
Group type: OTHER
Intervention: Rivastigmine Patch
Description: Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
Study: NCT00308971

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
Study: NCT01619033

Intervention type: DRUG
Group type: OTHER
Intervention: BF2.649
Description: single dose 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: single dose 20 mg
Study: NCT06381869

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pea protein (NUTRALYS ® S85 plus) in water
Description: After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) in water containing 0,41 g of tested protein/kg of body weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pea protein (NUTRALYS ® S85 plus) in water
Description: After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) in water containing 0,41 g of tested protein/kg of body weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pea protein (NUTRALYS ® S85 plus) within meal
Description: After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) within a meal containing 0,41 g of tested protein/kg of body weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pea protein (NUTRALYS ® S85 plus) within meal
Description: After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) within a meal containing 0,41 g of tested protein/kg of body weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein in water
Description: After selection and randomization, the subjects will consume per os whey protein in water containing 0,41 g of tested protein/kg of body weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein in water
Description: After selection and randomization, the subjects will consume per os whey protein in water containing 0,41 g of tested protein/kg of body weight.
Study: NCT02605135

Intervention type: DEVICE
Intervention: Continued Pessary Use
Description: Pessary Fitting

Intervention type: DEVICE
Intervention: Continued Pessary Use
Description: Pessary Fitting
Study: NCT00465101

Intervention type: DEVICE
Group type: OTHER
Intervention: GreenLight HPS
Description: Greenlight HPS laser system for treatment of BPH
Study: NCT06381869

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein within meal
Description: After selection and randomization, the subjects will consume per os whey protein within a meal containing 0,41 g of tested protein/kg of body weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein within meal
Description: After selection and randomization, the subjects will consume per os whey protein within a meal containing 0,41 g of tested protein/kg of body weight.
Study: NCT01494610

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SERETIDE Rotacaps
Description: The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SERETIDE Rotacaps
Description: The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SERETIDE Diskus
Description: The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SERETIDE Diskus
Description: The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
Study: NCT00651027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-868554
Description: 200 mg, Child-Pugh Class A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-868554
Description: 200 mg, Child-Pugh Class B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-868554
Description: 200 mg, healthy volunteers
Study: NCT02263066

Intervention type: BIOLOGICAL
Intervention: BAY14-2222_Kogenate-FS FVIII
Description: Depends on Doctor's decision
Study: NCT03063996

Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral IV access procedure
Description: standard of care guided IV access into peripheral vein excluding IJ

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral IJ access procedure
Description: standard of care guided IV access into IJ
Study: NCT00594464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: 2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;~Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;~One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery.
Study: NCT03299842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 (Fenfluramine Hydrochloride)
Description: ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
Study: NCT03525197

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein-based supplement
Description: High quality protein supplement to be consumed twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen protein-based supplement
Description: Lower quality protein supplement to be consumed daily
Study: NCT02086929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Study: NCT01893424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex buccal spray
Description: buccal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD-THC-Piperine-PNL capsule
Description: a capsule containing Cannabidiol and Tetrahydrocannabinol combination
Study: NCT04734496

Intervention type: OTHER
Intervention: National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
Description: National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)

Intervention type: OTHER
Intervention: National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
Description: National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)

Intervention type: OTHER
Intervention: National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
Description: National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
Study: NCT03395314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1 single dose of IV ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: 1 single dose of IV midazolam
Study: NCT02385799

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline Liquid Placebo
Description: Liquid placebo given in parallel to active medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Active medication
Study: NCT00308971

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for alpha lipoic acid; 2 pills daily for 4 months
Study: NCT00685113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-3001
Description: 4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
Study: NCT02654561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin Sodium
Description: A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
Study: NCT00685113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-3001
Description: 6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
Study: NCT02654561

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
Study: NCT01768572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab
Description: Pharmaceutical form: solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxychloroquine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfasalazine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfasalazine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfasalazine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide
Description: Dispensed according to local practice.
Study: NCT01737359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amdoxovir 300 mg bid
Description: 2 x 150 mg capsules bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amdoxovir 500 mg bid
Description: 2 x 250 mg capsules bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir DF 300 mg qd
Description: 1 x 300 mg tablet once daily
Study: NCT04082494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music via internet and noise canceling headphones
Description: Optional music via internet and noise canceling headphones will be offered.